 |
|
Willingness to Pay for Complete Symptom Relief of Gastroesophageal Reflux Disease
Leah Kleinman, DrPH;
Emma McIntosh, MSc;
Mandy Ryan, PhD;
Jordana Schmier, MA;
Joseph Crawley, MS;
G. Richard Locke III, MD;
Gregory de Lissovoy, PhD
Arch Intern Med. 2002;162:1361-1366.
Background Over $6 billion per year is spent on prescription medication for gastroesophageal
reflux disease (GERD). This study is an economic analysis of patients' willingness
to pay for a prescription medication that offers complete relief of GERD symptoms.
Methods The study was a cross-sectional, nonrandomized design recruiting patients
from 5 clinical sites. A computer-administered discrete-choice questionnaire
was used to explore patients' willingness to pay for various attributes (time
to relief, amount of relief, side effects, and out-of-pocket cost) associated
with GERD treatment. Patients chose between 2 different combinations of attributes
by indicating which scenario they preferred. Data were gathered on health
status, health-related quality of life, and sociodemographic characteristics.
Results Two hundred five patients completed the discrete-choice questionnaire
with a consistency rate of 99.5%. All attributes were relevant to patient
decision making. Respondents were willing to pay up to $182 to obtain complete
relief in a short period of time without side effects. Patients with less
severe GERD symptoms were willing to pay more to avoid side effects ($58.25
vs $38.43). Older patients were less willing to pay for better relief than
younger patients.
Conclusions Results demonstrate that patients are willing to pay more per month
for a medication that provides more complete and faster relief from GERD symptoms.
This information can guide clinicians and formulary committees in evaluating
optimal treatment for GERD.
From MEDTAP International, Bethesda, Md (Drs Kleinman and de Lissovoy
and Ms Schmier); the Health Economics Research Center, University of Oxford,
Oxford, England (Ms McIntosh); the Health Economics Research Unit, University
of Aberdeen, Aberdeen, Scotland (Dr Ryan); AstraZeneca LP, Wayne, Pa (Mr Crawley);
and the Mayo Clinic, Rochester, Minn (Dr Locke).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands
Kirchhoff et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2006;291:G838-G843.
ABSTRACT
| FULL TEXT
High-Risk Individuals' Willingness to Pay for Diabetes Risk-Reduction Programs.
Johnson et al.
Diabetes Care 2006;29:1351-1356.
ABSTRACT
| FULL TEXT
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs
Dent et al.
Gut 2004;53:iv1-iv24.
ABSTRACT
| FULL TEXT
|
